Gregory Russotti
Förmögenhet: 1 M $ per 2026-05-31
Förmögenhet: 1 M $ per 2026-05-31
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. since 2023.
Formerly, Dr. Russotti was VP, Cell Therapy Development and Operations at Celgene Corp.
from 2013 to 2019.
Education includes a doctorate from Rutgers State University of New Jersey conferred in 1996, and undergraduate and graduate degrees from Rensselaer Polytechnic Institute conferred in 1988 and 1990, respectively.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-06-12 | 605 092 ( 0,34 % ) | 1 M $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2020-01-01 |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Konsult / Rådgivare | - |
| Företag | Position | Slut |
|---|---|---|
| CELGENE | Företagsledare/Principal | 2019-12-31 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Finance |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån